Northern Trust Corp Galectin Therapeutics Inc Transaction History

Northern Trust Corp

  • $658 Billion
  • Q1 2025

A detailed history of Northern Trust Corp transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Northern Trust Corp holds 170,227 shares of GALT stock, worth $415,353. This represents 0.0% of its overall portfolio holdings.

Number of Shares
170,227
Previous 244,274 30.31%
Holding current value
$415,353
Previous $290,000 28.62%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
SELL
$1.1 - $1.76 $81,451 - $130,322
-74,047 Reduced 30.31%
170,227 $207,000
Q4 2024

Feb 14, 2025
BUY
$0.87 - $3.0 $8,694 - $29,982
9,994 Added 4.27%
244,274 $290,000
Q3 2024

Nov 13, 2024
BUY
$2.04 - $2.86 $218,904 - $306,895
107,306 Added 84.51%
234,280 $644,000
Q2 2024

Aug 14, 2024
BUY
$2.13 - $4.2 $55,002 - $108,456
25,823 Added 25.53%
126,974 $286,000
Q1 2024

May 14, 2024
BUY
$1.6 - $2.44 $206 - $314
129 Added 0.13%
101,151 $241,000
Q4 2023

Feb 13, 2024
SELL
$1.6 - $2.18 $1,507 - $2,053
-942 Reduced 0.92%
101,022 $167,000
Q2 2023

Aug 11, 2023
BUY
$1.32 - $2.08 $9,511 - $14,988
7,206 Added 7.6%
101,964 $146,000
Q1 2023

May 15, 2023
BUY
$1.1 - $2.4 $10,884 - $23,748
9,895 Added 11.66%
94,758 $198,000
Q4 2022

Feb 13, 2023
SELL
$1.03 - $1.66 $401 - $647
-390 Reduced 0.46%
84,863 $95,000
Q3 2022

Nov 14, 2022
SELL
$1.31 - $2.48 $6,036 - $11,427
-4,608 Reduced 5.13%
85,253 $139,000
Q2 2022

Aug 12, 2022
SELL
$1.19 - $1.74 $4,375 - $6,397
-3,677 Reduced 3.93%
89,861 $118,000
Q1 2022

May 13, 2022
SELL
$1.61 - $2.31 $724 - $1,039
-450 Reduced 0.48%
93,538 $150,000
Q4 2021

Feb 08, 2022
BUY
$2.07 - $3.8 $10,697 - $19,638
5,168 Added 5.82%
93,988 $194,000
Q3 2021

Nov 15, 2021
SELL
$2.59 - $4.15 $19,295 - $30,917
-7,450 Reduced 7.74%
88,820 $345,000
Q2 2021

Aug 13, 2021
SELL
$2.07 - $5.1 $672,404 - $1.66 Million
-324,833 Reduced 77.14%
96,270 $309,000
Q1 2021

May 12, 2021
SELL
$1.96 - $2.57 $62,433 - $81,864
-31,854 Reduced 7.03%
421,103 $913,000
Q4 2020

Feb 11, 2021
SELL
$2.24 - $2.87 $29,135 - $37,330
-13,007 Reduced 2.79%
452,957 $1.01 Million
Q3 2020

Nov 16, 2020
SELL
$2.53 - $3.64 $71,814 - $103,321
-28,385 Reduced 5.74%
465,964 $1.25 Million
Q2 2020

Aug 14, 2020
SELL
$1.66 - $3.15 $37,657 - $71,457
-22,685 Reduced 4.39%
494,349 $1.51 Million
Q1 2020

May 14, 2020
BUY
$1.51 - $3.0 $40,350 - $80,166
26,722 Added 5.45%
517,034 $1.01 Million
Q4 2019

Feb 14, 2020
BUY
$2.79 - $4.32 $2,438 - $3,775
874 Added 0.18%
490,312 $1.4 Million
Q3 2019

Nov 13, 2019
BUY
$3.0 - $4.05 $1.07 Million - $1.44 Million
355,322 Added 264.94%
489,438 $1.8 Million
Q2 2019

Aug 13, 2019
BUY
$3.61 - $5.0 $160,085 - $221,725
44,345 Added 49.4%
134,116 $556,000
Q1 2019

May 13, 2019
BUY
$3.86 - $6.02 $10,958 - $17,090
2,839 Added 3.27%
89,771 $458,000
Q4 2018

Feb 12, 2019
SELL
$3.43 - $5.74 $3,268 - $5,470
-953 Reduced 1.08%
86,932 $298,000
Q3 2018

Nov 14, 2018
BUY
$3.68 - $6.93 $4,662 - $8,780
1,267 Added 1.46%
87,885 $529,000
Q2 2018

Aug 14, 2018
BUY
$3.16 - $9.16 $23,263 - $67,435
7,362 Added 9.29%
86,618 $551,000
Q1 2018

May 09, 2018
SELL
$3.78 - $5.97 $16,677 - $26,339
-4,412 Reduced 5.27%
79,256 $376,000
Q4 2017

Feb 14, 2018
BUY
$1.54 - $3.34 $4,510 - $9,782
2,929 Added 3.63%
83,668 $279,000
Q3 2017

Nov 13, 2017
BUY
$1.67 - $2.3 $134,834 - $185,699
80,739
80,739 $173,000

Others Institutions Holding GALT

# of Institutions
103
Shares Held
10.1M
Call Options Held
587K
Put Options Held
2.02M
View Full List

About GALECTIN THERAPEUTICS INC

GALT Quotes by TradingView
  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $145M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email